Pancreatic cancer inhibition by specific knockdown of K-ras mutant allele expression

Cancer Biology and Therapy

Volumn 6, Issue 2, 2007, Pages 293-294

  Bernhard, Eric J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

K RAS; Oncogene; Pancreatic carcinoma; RNAL; shRNA

Indexed keywords

K RAS PROTEIN;

ALLELE; CANCER INHIBITION; GENE EXPRESSION; HUMAN; NOTE; ONCOGENE K RAS; PANCREAS CANCER;

EID: 34247386767     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.6.2.4025     Document Type: Note

References (22)

1. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988; 53:549-54.
2. Smit VT, Boot AJ, Smits AM, Fleuren GJ, Cornelisse CJ, Bos JL. KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas. 1988; 16:7773-82.
3. Varghese HJ, Davidson MT, MacDonald IC, Wilson SM, Nadkarni KV, Groom AC, Chambers AF. Activated ras regulates the proliferation/apoptosis balance and early survival of developing micrometastases. Cancer Res 2002; 62:887-91.
4. Smakman N, Borel Rinkes IH, Voest EE, Kranenburg O. Control of colorectal metastasis formation by K-Ras. Biochim Biophys Acta 2005; 1756:103-14.
5. Bernhard EJ, Stanbridge EJ, Gupta S, Gupta AK, Soto D, Bakanauskas VJ, Cerniglia GJ, Muschel RJ, McKenna WG. Direct evidence for the contribution of activated N-ras and K-ras oncogenes to increased intrinsic radiation resistance in human tumor cell lines. Cancer Res 2000; 60:6597-600.
6. Levy E, Baroche C, Barret JM, Alapetite C, Salles B, Averbeck D, Moustacchi E. Activated ras oncogene and specifically acquired resistance to cisplatin in human mammary epithelial cells: induction of DNA cross-links and their repair. Carcinogenesis 1994; 15:845-50.
7. Nemunaitis J, Cox J, Meyer W, Courtney A, Mues G. Irinotecan hydrochloride (CPT-11) resistance identified by K-ras mutation in patients with progressive colon cancer after treatment with 5-fluorouracil (5-FU). American Journal of Clinical Oncology 1997; 20:527-9.
8. Garcea G, Neal CP, Pattenden CJ, Steward WP, Berry DP. Molecular prognostic markers in pancreatic cancer: a systematic review. Eur J Cancer 2005; 41:2213-36.
9. Cox AD, Der CJ. Ras family signaling: therapeutic targeting. Cancer Biol Ther 2002; 1:599-606.
10. Brunner TB, Hahn SM, Gupta AK, Muschel RJ, McKenna WG, Bernhard EJ. Farnesyltransferase inhibitors: an overview of the results of preclinical and clinical investigations. Cancer Res 2003; 63:5656-68.
11. Rowinsky EK. Lately, it occurs to me what a long, strange trip it's been for the farnesyltransferase inhibitors. J Clin Oncol 2006; 24:2981-4.
12. Kashani-Sabet M, Funato T, Florenes VA, Fodstad O, Scanlon KJ. Suppression of the neoplastic phenotype in vivo by an anti-ras ribozyme. Cancer Res 1994; 54:900-2.
13. Kita K, Saito S, Morioka CY, Watanabe A. Growth inhibition of human pancreatic cancer cell lines by anti-sense oligonucleotides specific to mutated K-ras genes. International Journal of Cancer 1999; 80:553-8.
14. Tsuchida T, Kijima H, Hori S, Oshika Y, Tokunaga T, Kawai K, Yamazaki H, Ueyama Y, Scanlon KJ, Tamaoki N, Nakamura M. Adenovirus-mediated anti-K-ras ribozyme induces apoptosis and growth suppression of human pancreatic carcinoma. Cancer Gene Ther 2000; 7:373-83.
15. Nakano M, Aoki K, Matsumoto N, Ohnami S, Hatanaka K, Hibi T, Terada M, Yoshida T. Suppression of colorectal cancer growth using an adenovirus vector expressing an antisense K-ras RNA. Mol Ther 2001; 3:491-9.
16. Zhang YA, Nemunaitis J, Samuel SK, Chen P, Shen Y, Tong AW. Antitumor activity of an oncolytic adenovirus-delivered oncogene small interfering RNA. Cancer Res 2006; 66:9736-43.
17. Gibbs JB, Graham SL, Hartman GD, Koblan KS, Kohl NE, Omer CA, Oliff A. Farnesyltransferase inhibitors versus Ras inhibitors. Current Opinion in Chemical Biology 1997; 1:197-203.
18. Lerner EC, Zhang TT, Knowles DB, Qian Y, Hamilton AD, Sebti SM. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines. Oncogene 1997; 15:1283-8.
19. Zhang FL, Kirschmeier P, Carr D, James L, Bond RW, Wang L, Patton R, Windsor WT, Syto R, Zhang R, Bishop WR. Characterization of Ha-ras, N-ras, Ki-Ras4A, and Ki-Ras4B as in vitro substrates for farnesyl protein transferase and geranylgeranyl protein transferase type I. J Biol Chem 1997; 272:10232-3239.
20. Zhu H, Liang ZY, Ren XY, Liu TH. Small Interfering RNAs Targeting Mutant K-ras Inhibit Human Pancreatic Carcinoma Cells Growth In Vitro and In Vivo. Cancer Biol Ther 2006; 5:1693-8.
21. Plattner R, Anderson MJ, Sato KY, Fasching CL, Der CJ, Stanbridge EJ. Loss of oncogenic ras expression does not correlate with loss of tumorigenicity in human cells. Proceedings of the National Academy of Sciences of the United States of America 1996; 93:6665-70.
22. Okada F, Rak JW, Croix BS, Lieubeau B, Kaya M, Roncari L, Shirasawa S, Sasazuki T, Kerbel RS. Impact of oncogenes in tumor angiogenesis: mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells. Proceedings of the National Academy of Sciences of the United States of America 1998; 95:3609-14.